Table 1.
Response to Proinflammatory and Pathogen-Derived Factors.
| CC | LPS | Poly I:C | CpG ODN | |||||
| DC | DR+IC | DC | DR+IC | DC | DR+IC | DC | DR+IC | |
| CD40 | 351.9 ± 52.3** | 82.4 ± 8.7** | 344.4 ± 45.6** | 122.0 ± 12.9** | 175.6 ± 76.5** | 57.9 ± 28.4** | 218.3 ± 21.5 | 93.9 ± 33.3 |
| CD80 | 17.3 ± 4.6** | 0.6 ± 1.4** | 34.7 ± 8.3** | 4.4 ± 1.5** | 22.6 ± 6.6** | 3.5 ± 0.8** | 10.0 ± 1.7 | 3.7 ± 3.3 |
| CD83 | 65.2 ± 12.9** | 9.14 ± 2.8** | 40.9 ± 5.0*** | 10.0 ± 2.3*** | 20.3 ± 9.2** | 6.4 ± 1.9** | 77.9 ± 13.2* | 24.3 ± 16.1* |
| CD86 | 729.51 ± 100.*** | 314.5 ± 6.3*** | 703.6 ± 85.6*** | 22.9 ± 10.6*** | 348.7 ± 159.5* | 21.8 ± 5.3* | 477.2 ± 32.9*** | 3.6 ± 1.6*** |
| HLA-DR | 1046.5 ± 20.6* | 273.9 ± 47.3* | 1044.1 ± 56.7* | 168.9 ± 60.7* | 458.0 ± 70.8** | 135.8 ± 29.0** | 663.6 ± 209.5 | 297.5 ± 120.7 |
†
Phenotypic maturation of DC and DR+IC was analyzed in PBMC following incubation with a combination of proinflammatory cytokines (TNF-α, IL-1β, IL-6, and PGE2; CC) or pathogen-derived factors, including ligands for TLR4 (LPS), TLR3 (poly I:C), and TLR9 (CpG ODN). Data were collected from 16 patients with breast cancer (stage II, n = 9; stage IV, n = 7). The magnitude of the response is expressed as ΔMFI (MFI of stimulated cells - MFI of unstimulated cells) ± SEM. Statistically significant differences between DC and DR+IC are indicated.
*
P < .05.
**
P < .01.
***
P < .001.